enGene Therapeutics Inc. (ENGN) stock intrinsic value fair value estimate & owner earnings analysis

enGene (Montreal, Canada) is a clinical-stage biotech with no product revenue. Its one lead product, detalimogene voraplasmid (a non-viral gene therapy placed in the bladder), is aimed at BCG-unresponsive non-muscle-invasive bladder cancer. Early Phase 2 (LEGEND) data in 21 patients showed a 71% complete response at any time and 67% at three months; the company is working toward an FDA filing. These are preliminary single-arm results, and nothing is approved, contracted or in the bag. What the company has. At July 31, 2026 it held about $41 million in cash and $225 million in marketable securities (about $266 million), against about $25 million of Hercules Capital term debt, so roughly $241 million net, or about $3.4 a share on about 70 million shares. The November 2025 offering (about $149.5 million gross) and further 2026 financing rebuilt the balance after cash had fallen to $50 million in October 2025. The auditors' note states the company expects existing cash to fund operations for at least 12 months, so there is no near-term funding emergency. An earlier version of our analysis counted only cash and overlooked the securities, and wrongly concluded that the company had under six months of runway; those prior figures are not comparable. What it costs. Owner earnings (operating cash flow less working-capital swings, stock compensation and capital spending) were about -$47 million in fiscal 2024 (-$1.26 a share) and -$117 million in fiscal 2025 (-$2.29 a share). The nine months to July 2026 show operating cash burn of $78 million, or roughly $105 million a year, and stock compensation is running near $20 million a year. Burn is rising: the trailing actual change in fiscal 2025 was a 147% larger loss, and we assume spending roughly flat from here at about $105 million a year while the trial and filing work proceeds. Debt interest is small (about $2 million a year). Bear case: $0.10 a share. Business worth roughly zero, debt of $25 million, cash of $266 million less about $210 million of burn through two more years of trial and filing work, less about $25 million to wind down. This is the outcome if the pivotal data fail to hold up in durability (single-arm bladder cancer data in this class have lost response rates over time) or the FDA issues a rejection. Roughly the entire cash pile is consumed, and equity is left near zero. The Hercules loan is repaid first. Base case: $1.15 a share. We credit no value to the product, because approval and sales are not yet secured. The business is therefore worth $0, and shareholders own the net cash left after funding about 18 months of burn (about $160 million) to reach an FDA decision: about $81 million, or about $1.15 a share. This understates a drug that already has a 71% response rate, but we do not value things that have not yet happened. Bull case: $8.00 a share. The company's own lever executes: the FDA approves the product in 2027 and the launch is small but successful in the US bladder cancer niche. Cash flow stays negative through 2028, turns positive in 2030, reaches about $110 million a year by 2032 and holds until exclusivity runs out around 2040, after which we assume nothing persists. That business is worth about $317 million, plus $241 million of net cash, or about $8 a share. We did not model further products or other cancers because nothing beyond the lead candidate is in clinical testing. What could prove this wrong. The cases hinge on one product. If the FDA accepts the filing and approves faster, or the response rates stay near 70% at 12 months, value moves toward the bull case. If another equity raise is needed before data (which is likely before any launch), existing shares are diluted again. Competing bladder cancer products already on the market or in late trials (Anktiva, Keytruda, Johnson & Johnson's TAR-200, CG Oncology and UroGen candidates) could compress pricing or patient share even after approval. Why the margin-of-safety price is $1.20. We are not sure about the earnings level: it is a loss, and the only question is how big. The worst plausible event is a trial or filing failure after the cash is spent, which the structure can survive (low debt, no concentration in a customer or regulator), but equity would be near zero. If we are wrong about the approval timing or the burn, the shares are worth $0.10 to $1.15. The price assumes a two-to-three-year holding period, but the business pays nothing in the meantime, and it is spending the cash that supports the price. At $1.20, the price is about what is left in cash after funding the path to an FDA decision; from that price, the bull case implies roughly 20% a year if approval comes in 2027, while the bear case implies a loss of most of the price. The margin-of-safety price takes effect only once FDA approval is in hand with cash still above $150 million, which is the observable condition we set.